Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments

Xiaoxu Wei(Central South University), Yunhua Chen(Central South University), Xianjie Jiang(Central South University), Peng Miao(Central South University), Yiduo Liu(Central South University), Yongzhen Mo(Central South University), Daixi Ren(Central South University), Yuze Hua(Central South University), Boyao Yu(Central South University), Yujuan Zhou(Central South University), Qianjin Liao(Central South University), Hui Wang(Central South University), Bo Xiang(Central South University), Ming Zhou(Central South University), Xiaoling Li(Central South University), Guiyuan Li(Central South University), Yong Li(Baylor College of Medicine), Wei Xiong(Central South University), Zhaoyang Zeng(Central South University)
Molecular Cancer
January 4, 2021
Cited by 471Open Access
Full Text

Abstract

BACKGROUND: Vasculogenic mimicry (VM) is a recently discovered angiogenetic process found in many malignant tumors, and is different from the traditional angiogenetic process involving vascular endothelium. It involves the formation of microvascular channels composed of tumor cells; therefore, VM is considered a new model for the formation of new blood vessels in aggressive tumors, and can provide blood supply for tumor growth. Many studies have pointed out that in recent years, some clinical treatments against angiogenesis have not been satisfactory possibly due to the activation of VM. Although the mechanisms underlying VM have not been fully elucidated, increasing research on the soil "microenvironment" for tumor growth suggests that the initial hypoxic environment in solid tumors is inseparable from VM. MAIN BODY: In this review, we describe that the stemness and differentiation potential of cancer stem cells are enhanced under hypoxic microenvironments, through hypoxia-induced epithelial-endothelial transition (EET) and extracellular matrix (ECM) remodeling to form the specific mechanism of vasculogenic mimicry; we also summarized some of the current drugs targeting VM through these processes, suggesting a new reference for the clinical treatment of tumor angiogenesis. CONCLUSION: Overall, the use of VM inhibitors in combination with conventional anti-angiogenesis treatments is a promising strategy for improving the effectiveness of targeted angiogenesis treatments; further, considering the importance of hypoxia in tumor invasion and metastasis, drugs targeting the hypoxia signaling pathway seem to achieve good results.


Related Papers